메뉴 건너뛰기




Volumn 74, Issue 3, 2008, Pages 724-735

Overcoming S-phase checkpoint-mediated resistance: Sequence-dependent synergy of gemcitabine and 7-ethyl-10-hydroxycamptothecin (SN-38) in human carcinoma cell lines

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CHECKPOINT KINASE 1; GEMCITABINE; IRINOTECAN;

EID: 50449109440     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.108.047787     Document Type: Article
Times cited : (10)

References (40)
  • 3
    • 0033368083 scopus 로고    scopus 로고
    • Synergistic effect of gemcitabine and irinotecan (CPT-11) on breast and small cell lung cancer cell lines
    • Bahadori HR, Rocha Lima CM, Green MR, and Safa AR (1999) Synergistic effect of gemcitabine and irinotecan (CPT-11) on breast and small cell lung cancer cell lines. Anticancer Res 19:5423-5428.
    • (1999) Anticancer Res , vol.19 , pp. 5423-5428
    • Bahadori, H.R.1    Rocha Lima, C.M.2    Green, M.R.3    Safa, A.R.4
  • 4
    • 0024847290 scopus 로고
    • What is synergy?
    • Berenbaum MC (1989) What is synergy? Pharmacol Rev 41:93-141.
    • (1989) Pharmacol Rev , vol.41 , pp. 93-141
    • Berenbaum, M.C.1
  • 5
    • 0021118703 scopus 로고
    • Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors
    • Chou TC and Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27-55.
    • (1984) Adv Enzyme Regul , vol.22 , pp. 27-55
    • Chou, T.C.1    Talalay, P.2
  • 6
    • 0037059331 scopus 로고    scopus 로고
    • 2 arrests induced by topoisomerase I poisons are dependent on ATR kinase function
    • 2 arrests induced by topoisomerase I poisons are dependent on ATR kinase function. J Biol Chem 277:1599-1606.
    • (2002) J Biol Chem , vol.277 , pp. 1599-1606
    • Cliby, W.A.1    Lewis, K.A.2    Lilly, K.K.3    Kaufmann, S.H.4
  • 7
    • 0345688175 scopus 로고    scopus 로고
    • Nucleoside anticancer drugs: The role of nucleoside transporters in resistance to cancer chemotherapy
    • Damaraju VL, Damaraju S, Young JD, Baldwin SA, Mackey J, Sawyer MB, and Cass CE (2003) Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene 22:7524-7536.
    • (2003) Oncogene , vol.22 , pp. 7524-7536
    • Damaraju, V.L.1    Damaraju, S.2    Young, J.D.3    Baldwin, S.A.4    Mackey, J.5    Sawyer, M.B.6    Cass, C.E.7
  • 8
    • 0025133118 scopus 로고
    • Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons
    • D'Arpa P, Beardmore C, and Liu LF (1990) Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res 50:6919-6924.
    • (1990) Cancer Res , vol.50 , pp. 6919-6924
    • D'Arpa, P.1    Beardmore, C.2    Liu, L.F.3
  • 10
    • 0024388737 scopus 로고
    • Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells
    • Holm C, Covey JM, Kerrigan D, and Pommier Y (1989) Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res 49:6365-6368.
    • (1989) Cancer Res , vol.49 , pp. 6365-6368
    • Holm, C.1    Covey, J.M.2    Kerrigan, D.3    Pommier, Y.4
  • 11
    • 0024420685 scopus 로고
    • Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin
    • Hsiang YH, Lihou MG, and Liu LF (1989) Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49:5077-5082.
    • (1989) Cancer Res , vol.49 , pp. 5077-5082
    • Hsiang, Y.H.1    Lihou, M.G.2    Liu, L.F.3
  • 12
    • 0029060757 scopus 로고
    • Fludarabine- and gemcitabine-induced apoptosis: Incorporation of analogs into DNA is a critical event
    • Huang P and Plunkett W (1995) Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol 36:181-188.
    • (1995) Cancer Chemother Pharmacol , vol.36 , pp. 181-188
    • Huang, P.1    Plunkett, W.2
  • 13
    • 0036330373 scopus 로고    scopus 로고
    • A dose-escalation study of irinotecan (CPT-11) in combination with gemcitabine in patients with advanced non-small cell lung cancer previously treated with a cisplatin-based front line chemotherapy
    • Kakolyris SS, Kouroussis C, Koukourakis M, Kalbakis K, Mavroudis D, Vardakis N, and Georgoulias V (2002) A dose-escalation study of irinotecan (CPT-11) in combination with gemcitabine in patients with advanced non-small cell lung cancer previously treated with a cisplatin-based front line chemotherapy. Anticancer Res 22:1891-1896.
    • (2002) Anticancer Res , vol.22 , pp. 1891-1896
    • Kakolyris, S.S.1    Kouroussis, C.2    Koukourakis, M.3    Kalbakis, K.4    Mavroudis, D.5    Vardakis, N.6    Georgoulias, V.7
  • 15
    • 0035884184 scopus 로고    scopus 로고
    • Reutilization of immunoblots after chemiluminescent detection
    • Kaufmann SH (2001) Reutilization of immunoblots after chemiluminescent detection. Anal Biochem 296:283-286.
    • (2001) Anal Biochem , vol.296 , pp. 283-286
    • Kaufmann, S.H.1
  • 16
    • 0030933933 scopus 로고    scopus 로고
    • Altered formation of topotecan-stabilized topoisomerase I-DNA adducts in human leukemia cells
    • Kaufmann SH, Svingen PA, Gore SD, Armstrong DK, Cheng YC, and Rowinsky EK (1997) Altered formation of topotecan-stabilized topoisomerase I-DNA adducts in human leukemia cells. Blood 89:2098-2104.
    • (1997) Blood , vol.89 , pp. 2098-2104
    • Kaufmann, S.H.1    Svingen, P.A.2    Gore, S.D.3    Armstrong, D.K.4    Cheng, Y.C.5    Rowinsky, E.K.6
  • 18
    • 0344443643 scopus 로고    scopus 로고
    • Fas-associated death domain protein in apoptosis induction by the mitogen-activated protein kinase kinase inhibitor CI-1040 (PD184352) in acute lymphocytic leukemia cells in vitro
    • Meng XW, Chandra J, Loegering D, Van Becelaere K, Kottke TJ, Gore SD, Karp JE, Sebolt-Leopold J, and Kaufmann SH (2003) Fas-associated death domain protein in apoptosis induction by the mitogen-activated protein kinase kinase inhibitor CI-1040 (PD184352) in acute lymphocytic leukemia cells in vitro. J Biol Chem 278:47326-47339.
    • (2003) J Biol Chem , vol.278 , pp. 47326-47339
    • Meng, X.W.1    Chandra, J.2    Loegering, D.3    Van Becelaere, K.4    Kottke, T.J.5    Gore, S.D.6    Karp, J.E.7    Sebolt-Leopold, J.8    Kaufmann, S.H.9
  • 20
    • 0031684654 scopus 로고    scopus 로고
    • Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: Elevated dTTP pools and enhanced cytotoxicity
    • Mullany S, Svingen PA, Kaufmann SH, and Erlichman C (1998) Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity. Cancer Chemother Pharmacol 42:391-399.
    • (1998) Cancer Chemother Pharmacol , vol.42 , pp. 391-399
    • Mullany, S.1    Svingen, P.A.2    Kaufmann, S.H.3    Erlichman, C.4
  • 21
    • 0028204160 scopus 로고
    • DNA strand breaks: The DNA template alterations that trigger p53-dependent DNA damage response pathways
    • Nelson WG and Kastan MB (1994) DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol 14:1815-1823.
    • (1994) Mol Cell Biol , vol.14 , pp. 1815-1823
    • Nelson, W.G.1    Kastan, M.B.2
  • 23
    • 0028799108 scopus 로고
    • Gemcitabine: Metabolism, mechanisms of action, and self-potentiation
    • Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, and Gandhi V (1995) Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 22 (4 Suppl 11):3-10.
    • (1995) Semin Oncol , vol.22 , Issue.4 SUPPL. 11 , pp. 3-10
    • Plunkett, W.1    Huang, P.2    Xu, Y.Z.3    Heinemann, V.4    Grunewald, R.5    Gandhi, V.6
  • 24
    • 33749034730 scopus 로고    scopus 로고
    • Topoisomerase I inhibitors: Camptothecins and beyond
    • Pommier Y (2006) Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 6:789-802.
    • (2006) Nat Rev Cancer , vol.6 , pp. 789-802
    • Pommier, Y.1
  • 26
    • 4644327989 scopus 로고    scopus 로고
    • Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate
    • Rocha Lima CM, Green MR, Rotche R, Miller WH Jr, Jeffrey GM, Cisar LA, Morganti A, Orlando N, Gruia G, and Miller LL (2004) Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 22:3776-3783.
    • (2004) J Clin Oncol , vol.22 , pp. 3776-3783
    • Rocha Lima, C.M.1    Green, M.R.2    Rotche, R.3    Miller Jr, W.H.4    Jeffrey, G.M.5    Cisar, L.A.6    Morganti, A.7    Orlando, N.8    Gruia, G.9    Miller, L.L.10
  • 27
    • 0036498787 scopus 로고    scopus 로고
    • Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer
    • Rocha Lima CM, Savarese D, Bruckner H, Dudek A, Eckardt J, Hainsworth J, Yunus F, Lester E, Miller W, Saville W, et al. (2002) Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol 20:1182-1191.
    • (2002) J Clin Oncol , vol.20 , pp. 1182-1191
    • Rocha Lima, C.M.1    Savarese, D.2    Bruckner, H.3    Dudek, A.4    Eckardt, J.5    Hainsworth, J.6    Yunus, F.7    Lester, E.8    Miller, W.9    Saville, W.10
  • 29
    • 33847304461 scopus 로고    scopus 로고
    • Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and leukemia group B study 39902
    • Rocha-Lima CM, Herndon JE 2nd, Lee ME, Atkins JN, Mauer A, Vokes E, and Green MR (2007) Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: cancer and leukemia group B study 39902. Ann Oncol 18:331-337.
    • (2007) Ann Oncol , vol.18 , pp. 331-337
    • Rocha-Lima, C.M.1    Herndon 2nd, J.E.2    Lee, M.E.3    Atkins, J.N.4    Mauer, A.5    Vokes, E.6    Green, M.R.7
  • 30
    • 0028105119 scopus 로고
    • Schedule dependence of sensitivity to 2′,2′- difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours
    • Ruiz van Haperen VW, Veerman G, Boven E, Noordhuis P, Vermorken JB, and Peters GJ (1994) Schedule dependence of sensitivity to 2′,2′- difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours. Biochem Pharmacol 48:1327-1339.
    • (1994) Biochem Pharmacol , vol.48 , pp. 1327-1339
    • Ruiz van Haperen, V.W.1    Veerman, G.2    Boven, E.3    Noordhuis, P.4    Vermorken, J.B.5    Peters, G.J.6
  • 31
    • 50449101282 scopus 로고    scopus 로고
    • Cytidine Analogues
    • Chabner BA and Lango DL eds pp, Lippincott Williams & Wilkins, Baltimore, MD
    • Ryan DP, Garcia-Carbonero R, and Chabner BA (2006) Cytidine Analogues, in Cancer Chemotherapy and Biotherapy (Chabner BA and Lango DL eds) pp 183-211, Lippincott Williams & Wilkins, Baltimore, MD.
    • (2006) Cancer Chemotherapy and Biotherapy , pp. 183-211
    • Ryan, D.P.1    Garcia-Carbonero, R.2    Chabner, B.A.3
  • 32
    • 34548598180 scopus 로고    scopus 로고
    • A phase I study of bi-weekly administration of 24-h gemcitabine followed by 24-h irinotecan in patients with solid tumors
    • Saif MW, Sellers S, Li M, Wang W, Cusimano L, Wang H, and Zhang R (2007) A phase I study of bi-weekly administration of 24-h gemcitabine followed by 24-h irinotecan in patients with solid tumors. Cancer Chemother Pharmacol 60:871-882.
    • (2007) Cancer Chemother Pharmacol , vol.60 , pp. 871-882
    • Saif, M.W.1    Sellers, S.2    Li, M.3    Wang, W.4    Cusimano, L.5    Wang, H.6    Zhang, R.7
  • 33
    • 20344383750 scopus 로고    scopus 로고
    • Preclinical evaluation of gemcitabine combination regimens for application in acute myeloid leukemia
    • Shanks RH, Rizzieri DA, Flowers JL, Colvin OM, and Adams DJ (2005) Preclinical evaluation of gemcitabine combination regimens for application in acute myeloid leukemia. Clin Cancer Res 11:4225-4233.
    • (2005) Clin Cancer Res , vol.11 , pp. 4225-4233
    • Shanks, R.H.1    Rizzieri, D.A.2    Flowers, J.L.3    Colvin, O.M.4    Adams, D.J.5
  • 34
    • 0035116697 scopus 로고    scopus 로고
    • S-Phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine
    • Shi Z, Azuma A, Sampath D, Li YX, Huang P, and Plunkett W (2001) S-Phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine. Cancer Res 61:1065-1072.
    • (2001) Cancer Res , vol.61 , pp. 1065-1072
    • Shi, Z.1    Azuma, A.2    Sampath, D.3    Li, Y.X.4    Huang, P.5    Plunkett, W.6
  • 36
    • 34547134312 scopus 로고    scopus 로고
    • Topoisomerase I-targeting drugs
    • Chabner BA and Longo DL eds pp, Lippincott Williams & Wilkins, Baltimore, MD
    • Sparreboom A and Zamboni WC (2006) Topoisomerase I-targeting drugs, in Cancer Chemotherapy and Biotherapy (Chabner BA and Longo DL eds) pp 371-413, Lippincott Williams & Wilkins, Baltimore, MD.
    • (2006) Cancer Chemotherapy and Biotherapy , pp. 371-413
    • Sparreboom, A.1    Zamboni, W.C.2
  • 37
    • 33748297529 scopus 로고    scopus 로고
    • A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer
    • Stathopoulos GP, Syrigos K, Aravantinos G, Polyzos A, Papakotoulas P, Fountzilas G, Potamianou A, Ziras N, Boukovinas J, Varthalitis J, et al. (2006) A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer 95:587-592.
    • (2006) Br J Cancer , vol.95 , pp. 587-592
    • Stathopoulos, G.P.1    Syrigos, K.2    Aravantinos, G.3    Polyzos, A.4    Papakotoulas, P.5    Fountzilas, G.6    Potamianou, A.7    Ziras, N.8    Boukovinas, J.9    Varthalitis, J.10
  • 38
    • 37049019520 scopus 로고    scopus 로고
    • A phase 1 study of fixed dose rate gemcitabine and irinotecan in patients with advanced pancreatic and biliary cancer
    • Sun W, Hewitt MR, Theobald MR, Hershock D, and Haller DG (2007) A phase 1 study of fixed dose rate gemcitabine and irinotecan in patients with advanced pancreatic and biliary cancer. Cancer 110:2768-2774.
    • (2007) Cancer , vol.110 , pp. 2768-2774
    • Sun, W.1    Hewitt, M.R.2    Theobald, M.R.3    Hershock, D.4    Haller, D.G.5
  • 39
    • 0018198132 scopus 로고
    • Deoxycytidine kinase and cytosine nucleoside deaminase activities in synchronized cultures of normal rat kidney cells
    • Wan CW and Mak TW (1978) Deoxycytidine kinase and cytosine nucleoside deaminase activities in synchronized cultures of normal rat kidney cells. Cancer Res 38:2768-2772.
    • (1978) Cancer Res , vol.38 , pp. 2768-2772
    • Wan, C.W.1    Mak, T.W.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.